Talis Biomedical (Talis Biomedical) Inventory-to-Revenue : 0.00 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Talis Biomedical Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Talis Biomedical's Average Total Inventories for the quarter that ended in Mar. 2024 was $0.00 Mil. Talis Biomedical's Revenue for the three months ended in Mar. 2024 was $0.07 Mil. Talis Biomedical's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.00.

Talis Biomedical's Inventory-to-Revenue for the quarter that ended in Mar. 2024 stayed the same from Dec. 2023 (0.00) to Dec. 2023 (0.00)

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Talis Biomedical's Days Inventory for the three months ended in Mar. 2024 was 0.00.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Talis Biomedical Inventory-to-Revenue Historical Data

The historical data trend for Talis Biomedical's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Talis Biomedical Inventory-to-Revenue Chart

Talis Biomedical Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventory-to-Revenue

Get a 7-Day Free Trial

Talis Biomedical Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Inventory-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Talis Biomedical's Inventory-to-Revenue

For the Medical Devices subindustry, Talis Biomedical's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Talis Biomedical's Inventory-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Talis Biomedical's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Talis Biomedical's Inventory-to-Revenue falls into.

Talis Biomedical Inventory-to-Revenue Calculation

Talis Biomedical's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

	Inventory-to-Revenue (A: Dec. 2023 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Dec. 2022 )	+	Total Inventories (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )
=	( (0	+	0)	/	1 )	/	0.412
=	0					/	0.412
=	0.00

Talis Biomedical's Inventory-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

	Inventory-to-Revenue (Q: Mar. 2024 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Dec. 2023 )	+	Total Inventories (Q: Mar. 2024 ))	/	count )	/	Revenue (Q: Mar. 2024 )
=	( (0	+	0)	/	1 )	/	0.073
=	0					/	0.073
=	0.00

Talis Biomedical (NAS:TLIS) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Talis Biomedical's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2024 )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
	=	0	/	0.006	*	365 / 4
	=	0.00

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Talis Biomedical's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Mar. 2024 )	/	Average Total Inventories (Q: Mar. 2024 )
	=	0.006	/	0
	=

Talis Biomedical Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Talis Biomedical's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Talis Biomedical (Talis Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Talis Biomedical Corp (NAS:TLIS) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

3400 Bridge Parkway, Redwood City, CA, USA, 94065

Website

https://talisbio.com

Talis Biomedical Corp is engaged in developing and commercializing products designed to enable molecular testing for infectious diseases and other conditions at the point-of-care. Its Talis One System is a molecular diagnostic platform developed to enable point-of-care testing for infectious diseases such as COVID-19.

Executives

Andrew A Lukowiak	officer: President, other: Chief Scientific Officer	1639 WINDEMERE DRIVE, SAN MARCOS CA 92078
Heinrich Dreismann	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Rebecca Markovich	officer: Interim CFO	CARS.COM INC., 300 S. RIVERSIDE PLAZA, SUITE 1000, CHICAGO IL 60606
Raymond Cheong	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Felix Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667,	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Brian J Blaser	director, officer: President and CEO	561 CIRCLE LANE, LAKE FOREST IL 60045
Ramesh Ramakrishnan	officer: Sr. Vice President, R&D	230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Randal W Scott	director	171 MAIN STREET #225, LOS ALTOS CA 94022
Jeryl L Hilleman	director	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Kimberly J Popovits	director	301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063